Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

G. Brittinger; H. Bartels; Harold Common; E. Dühmke; H.H. Fülle; U. Gunzer; T. Gyenes; R. Heinz; E König; P. Meusers; M. Paukstat; H. Pralle; H. Theml; Wolfgang Köpcke; C Thieme; T. Zwingers; K. Musshoff; A Stacher; H Brücher; F. Herrmann; W. D. Ludwig; W Pribilla; A. Burger‐Schüler; G. W. Löhr; H Gremmel; Joachim Oertel; H. Gerhartz; K.‐M. Koeppen; Irene Boll; D. Huhn; Thomas Binder; A. Schoengen; L. Nowicki; H.W. Pees; P. G. Scheurlen; H. Leopold; M. Wannenmacher; M. Schmidt; H. Löffler; G. Michlmayr; E. Thiel; R. Zettel; U Rühl; H. Wilke; E.‐W. Schwarze; H. Stein; A.C. Feller; K. Lennert; KIEL LYMPHOMA STUDY GROUP

doi:10.1002/hon.2900020306

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

G. Brittinger(Institut für Medizinische Informatik, Biometrie und Epidemiologie), H. Bartels(Ordensklinikum Linz Barmherzige Schwestern), Harold Common(University of Freiburg), E. Dühmke(Christian-Albrechts-Universität zu Kiel), H.H. Fülle(Malteser-Krankenhaus), U. Gunzer(University of Würzburg), T. Gyenes(Institut für Medizinische Informatik, Biometrie und Epidemiologie), R. Heinz(Hanusch Hospital), E König(Institut für Medizinische Informatik, Biometrie und Epidemiologie), P. Meusers(Institut für Medizinische Informatik, Biometrie und Epidemiologie), M. Paukstat(Institut für Medizinische Informatik, Biometrie und Epidemiologie), H. Pralle(Justus-Liebig-Universität Gießen), H. Theml(München Klinik Schwabing), Wolfgang Köpcke(Zimmer Biomet (Netherlands)), C Thieme(Ludwig-Maximilians-Universität München), T. Zwingers(Zimmer Biomet (Netherlands)), K. Musshoff(University of Freiburg), A Stacher(Hanusch Hospital), H Brücher(Freie Universität Berlin), F. Herrmann(Freie Universität Berlin), W. D. Ludwig(Freie Universität Berlin), W Pribilla(Malteser-Krankenhaus), A. Burger‐Schüler(München Klinik Schwabing), G. W. Löhr(University of Freiburg), H Gremmel(Christian-Albrechts-Universität zu Kiel), Joachim Oertel(Freie Universität Berlin), H. Gerhartz(Freie Universität Berlin), K.‐M. Koeppen(Jüdisches Krankenhaus Berlin), Irene Boll(Jüdisches Krankenhaus Berlin), D. Huhn(LMU Klinikum), Thomas Binder(Universität Ulm), A. Schoengen(Universität Ulm), L. Nowicki(St. Franziskus Hospital), H.W. Pees(Jüdisches Krankenhaus Berlin), P. G. Scheurlen(Universitätsklinikum des Saarlandes), H. Leopold(University of Freiburg), M. Wannenmacher(University of Freiburg), M. Schmidt(Evangelisches Diakoniekrankenhaus), H. Löffler(Justus-Liebig-Universität Gießen), G. Michlmayr(Ordensklinikum Linz Barmherzige Schwestern), E. Thiel(Ludwig-Maximilians-Universität München), R. Zettel(Ludwig-Maximilians-Universität München), U Rühl(Malteser-Krankenhaus), H. Wilke(University of Würzburg), E.‐W. Schwarze(Christian-Albrechts-Universität zu Kiel), H. Stein(Christian-Albrechts-Universität zu Kiel), A.C. Feller(Christian-Albrechts-Universität zu Kiel), K. Lennert(Christian-Albrechts-Universität zu Kiel), KIEL LYMPHOMA STUDY GROUP

Hematological Oncology

July 1, 1984

10.1002/hon.2900020306

Cited by 209

Abstract

Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas (NHL) was investigated in 1127 patients entering a prospective multicenter observation study. Survival of the 782 (69.4 per cent) patients with low-grade malignant NHL (lymphocytic lymphomas, predominantly B-CLL, LP immunocytoma, centrocytic lymphoma, centroblastic-centrocytic lymphoma) exceeded that of the 341 patients (30.2 per cent) with high-grade malignant NHL (centroblastic, immunoblastic, lymphoblastic lymphomas). Prognosis was best in centroblastic-centrocytic lymphoma and in B-CLL and least favorable in immunoblastic and lymphoblastic lymphomas. Survival of LP immunocytoma and centrocytic lymphoma patients was intermediate after 2 to 2.5 years of follow-up. Corresponding to histopathology, pattern of survival curves of low-grade malignant NHL (slow decline, no plateauing) differed from that of high-grade malignant NHL (rapid decline, subsequent plateauing). Prognosis of B-CLL was superior to that of LP immunocytoma. Stages I and II were more frequent in centroblastic-centrocytic lymphoma (21 per cent) than in LP immunocytoma (2.5 per cent) and centrocytic lymphoma (11 per cent). Ability of radiotherapy to induce stable complete remissions in stage III of centroblastic-centrocytic lymphoma indicates prolonged restriction of lymphoma to the lymphatic system. In immunoblastic and centroblastic lymphomas, stages I and II were diagnosed in 34 and 38 per cent of cases, respectively, but only in stage I/IE of centroblastic lymphoma prolonged remissions were achieved by radiotherapy. In advanced high-grade malignant NHL marked improvement of prognosis was solely possible by induction of complete remissions whereas in corresponding low-grade malignant lymphomas also partial remissions were prognostically relevant.

Edward L. Kaplan, Paul Meier|Springer series in statistics|1992|45.5k

Report of the Committee on Hodgkin's Disease Staging Classification.

Paul P. Carbone, Henry S. Kaplan, K. Musshoff et al.|PubMed|1971|4.2k

Clinical staging of chronic lymphocytic leukemia

KR Rai, A Sawitsky, Cronkite Ep et al.|Blood|1975|2.7k

ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE

V. T. DeVita, G. P. Canellos, Bruce A. Chabner et al.|The Lancet|1975|485

Gastrointestinal involvement in non-Hodgkin's lymphoma

Richard Herrmann, Alvin M. Panahon, Maurice Barcos et al.|Cancer|1980|442

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

Abstract

Related Papers